Polyplex Corporation Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 4, 2025, 1:33 am

Competitors of Polyplex Corporation Ltd

All Competitor Stocks of Polyplex Corporation Ltd

Quarterly Result

Last Updated: August 20, 2025, 5:25 am

Below is a detailed analysis of the quarterly data for Polyplex Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,739.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,740.00 Cr. (Mar 2025) to 1,739.00 Cr., marking a decrease of 1.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,739.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,676.00 Cr. (Mar 2025) to 1,739.00 Cr., marking an increase of 63.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Mar 2025) to -1.00 Cr., marking a decrease of 65.00 Cr..
• For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 4.00% (Mar 2025) to 0.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 12.00 Cr..
• For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 86.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 10.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -71.00 Cr.. The value appears to be declining and may need further review. It has decreased from -6.00 Cr. (Mar 2025) to -71.00 Cr., marking a decrease of 65.00 Cr..
• For Tax %, as of Jun 2025, the value is -15.00%. The value appears to be improving (decreasing) as expected. It has decreased from 54.00% (Mar 2025) to -15.00%, marking a decrease of 69.00%.
• For Net Profit, as of Jun 2025, the value is -60.00 Cr.. The value appears to be declining and may need further review. It has decreased from -9.00 Cr. (Mar 2025) to -60.00 Cr., marking a decrease of 51.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -6.15. The value appears to be declining and may need further review. It has decreased from 3.22 (Mar 2025) to -6.15, marking a decrease of 9.37.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:39 am

Growth

Last Updated: September 5, 2025, 12:25 pm

Balance Sheet

Last Updated: December 4, 2025, 1:48 am

Below is a detailed analysis of the balance sheet data for Polyplex Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
• For Reserves, as of Sep 2025, the value is 4,008.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,731.00 Cr. (Mar 2025) to 4,008.00 Cr., marking an increase of 277.00 Cr..
• For Borrowings, as of Sep 2025, the value is 968.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 882.00 Cr. (Mar 2025) to 968.00 Cr., marking an increase of 86.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 3,608.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,309.00 Cr. (Mar 2025) to 3,608.00 Cr., marking an increase of 299.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 8,616.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,954.00 Cr. (Mar 2025) to 8,616.00 Cr., marking an increase of 662.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 4,049.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,944.00 Cr. (Mar 2025) to 4,049.00 Cr., marking an increase of 105.00 Cr..
• For CWIP, as of Sep 2025, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 89.00 Cr., marking an increase of 53.00 Cr..
• For Investments, as of Sep 2025, the value is 328.00 Cr.. The value appears to be declining and may need further review. It has decreased from 340.00 Cr. (Mar 2025) to 328.00 Cr., marking a decrease of 12.00 Cr..
• For Other Assets, as of Sep 2025, the value is 4,150.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,634.00 Cr. (Mar 2025) to 4,150.00 Cr., marking an increase of 516.00 Cr..
• For Total Assets, as of Sep 2025, the value is 8,616.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,954.00 Cr. (Mar 2025) to 8,616.00 Cr., marking an increase of 662.00 Cr..

Notably, the Reserves (4,008.00 Cr.) exceed the Borrowings (968.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Polyplex Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 66.64. This value is within the healthy range. It has increased from 12.05 (Mar 24) to 66.64, marking an increase of 54.59.
• For Diluted EPS (Rs.), as of Mar 25, the value is 66.64. This value is within the healthy range. It has increased from 12.05 (Mar 24) to 66.64, marking an increase of 54.59.
• For Cash EPS (Rs.), as of Mar 25, the value is 205.72. This value is within the healthy range. It has increased from 123.08 (Mar 24) to 205.72, marking an increase of 82.64.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,177.06. It has decreased from 1,817.76 (Mar 24) to 1,177.06, marking a decrease of 640.70.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,177.06. It has decreased from 1,817.76 (Mar 24) to 1,177.06, marking a decrease of 640.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2,153.57. It has increased from 1,972.68 (Mar 24) to 2,153.57, marking an increase of 180.89.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 247.54. This value is within the healthy range. It has increased from 133.06 (Mar 24) to 247.54, marking an increase of 114.48.
• For PBIT / Share (Rs.), as of Mar 25, the value is 153.71. This value is within the healthy range. It has increased from 37.00 (Mar 24) to 153.71, marking an increase of 116.71.
• For PBT / Share (Rs.), as of Mar 25, the value is 139.29. This value is within the healthy range. It has increased from 23.74 (Mar 24) to 139.29, marking an increase of 115.55.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 111.89. This value is within the healthy range. It has increased from 27.02 (Mar 24) to 111.89, marking an increase of 84.87.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 65.44. This value is within the healthy range. It has increased from 11.83 (Mar 24) to 65.44, marking an increase of 53.61.
• For PBDIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 6.74 (Mar 24) to 11.49, marking an increase of 4.75.
• For PBIT Margin (%), as of Mar 25, the value is 7.13. This value is below the healthy minimum of 10. It has increased from 1.87 (Mar 24) to 7.13, marking an increase of 5.26.
• For PBT Margin (%), as of Mar 25, the value is 6.46. This value is below the healthy minimum of 10. It has increased from 1.20 (Mar 24) to 6.46, marking an increase of 5.26.
• For Net Profit Margin (%), as of Mar 25, the value is 5.19. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.19, marking an increase of 3.83.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.03. This value is below the healthy minimum of 8. It has increased from 0.59 (Mar 24) to 3.03, marking an increase of 2.44.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.55. This value is below the healthy minimum of 15. It has increased from 1.07 (Mar 24) to 5.55, marking an increase of 4.48.
• For Return on Capital Employeed (%), as of Mar 25, the value is 7.34. This value is below the healthy minimum of 10. It has increased from 1.87 (Mar 24) to 7.34, marking an increase of 5.47.
• For Return On Assets (%), as of Mar 25, the value is 2.61. This value is below the healthy minimum of 5. It has increased from 0.50 (Mar 24) to 2.61, marking an increase of 2.11.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.09, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.22. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.22, marking an increase of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has increased from 0.85 (Mar 24) to 0.89, marking an increase of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 2.78. This value is within the healthy range. It has decreased from 2.97 (Mar 24) to 2.78, marking a decrease of 0.19.
• For Quick Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.58, marking a decrease of 0.20.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.73. This value is within the healthy range. It has increased from 2.95 (Mar 24) to 4.73, marking an increase of 1.78.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.00. This value is below the healthy minimum of 20. It has decreased from 41.48 (Mar 24) to 15.00, marking a decrease of 26.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.16. This value is below the healthy minimum of 20. It has increased from 4.55 (Mar 24) to 6.16, marking an increase of 1.61.
• For Earning Retention Ratio (%), as of Mar 25, the value is 85.00. This value exceeds the healthy maximum of 70. It has increased from 58.52 (Mar 24) to 85.00, marking an increase of 26.48.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.84. This value exceeds the healthy maximum of 70. It has decreased from 95.45 (Mar 24) to 93.84, marking a decrease of 1.61.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 17.17. This value is within the healthy range. It has increased from 10.04 (Mar 24) to 17.17, marking an increase of 7.13.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.76. This value is within the healthy range. It has increased from 3.04 (Mar 24) to 8.76, marking an increase of 5.72.
• For Enterprise Value (Cr.), as of Mar 25, the value is 6,412.91. It has increased from 4,772.65 (Mar 24) to 6,412.91, marking an increase of 1,640.26.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.93. This value is below the healthy minimum of 1. It has increased from 0.75 (Mar 24) to 0.93, marking an increase of 0.18.
• For EV / EBITDA (X), as of Mar 25, the value is 8.10. This value is within the healthy range. It has decreased from 11.22 (Mar 24) to 8.10, marking a decrease of 3.12.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.55, marking an increase of 0.17.
• For Retention Ratios (%), as of Mar 25, the value is 84.99. This value exceeds the healthy maximum of 70. It has increased from 58.51 (Mar 24) to 84.99, marking an increase of 26.48.
• For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has increased from 0.69 (Mar 24) to 1.02, marking an increase of 0.33.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.38 (Mar 24) to 0.55, marking an increase of 0.17.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness